NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Summary

This research study involves studying a device as a possible treatment for metastatic melanoma in the brain. The purpose of this study is to obtain information on the safety and effectiveness of the study device, NovoTTF-200A, in melanoma participants with brain metastases when it is combined with Pembrolizumab. The name of the study device involved in this study is: \-- NovoTTF-200A The name of the drug used in this study is: \-- Pembrolizumab

Timeline

Start

2025-10-30

Primary completion

2025-12

Completion

2026-01

Outcome

Outcome not reported

Stopped: “Contract Issues”

Drugs

Indications